GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond
A Literature Review of Recent Advances (2023–2025)
📄 Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a transformative class of therapeutics in the management of Type 2 Diabetes Mellitus (T2DM), with growing evidence supporting their benefits beyond glycemic control. This literature review analyzes recent advances in GLP-1 RA research published between 2023 and 2025, focusing on their evolving role in obesity management, cardiovascular risk reduction, and potential neuroprotective applications. Clinical trials such as SURMOUNT, STEP, and SELECT have expanded the therapeutic outlook for agents like semaglutide and tirzepatide. This review also examines the pharmacological mechanisms, safety profiles, and comparative efficacy of different agents, while identifying emerging gaps in long-term outcomes and combination therapies. Overall, GLP-1 RAs are redefining the landscape of metabolic disease management.
🔎 Introduction
Type 2 Diabetes Mellitus (T2DM) continues to pose a global health burden, driving complications such as cardiovascular disease, renal failure, and premature mortality. Traditional antidiabetic therapies focus primarily on glycemic control but often fall short in addressing the multifactorial nature of T2DM. Over the last decade, GLP-1 receptor agonists have gained prominence due to their ability to improve not just blood glucose but also body weight, cardiovascular outcomes, and possibly cognitive decline. As the therapeutic landscape evolves rapidly, this review aims to synthesize recent research on GLP-1 RAs from 2023 to 2025, highlighting key findings, ongoing debates, and future implications.
📚 Key Sections (Sample Headers)
⚙️ Mechanism of Action and Drug Evolution
- GLP-1’s role in glucose regulation, satiety, and gastric emptying
- Comparison of first-gen vs. long-acting agents (e.g., liraglutide vs. semaglutide)
🧪 Recent Clinical Trials & Evidence (2023–2025)
- Overview of STEP, SELECT, and SURMOUNT trials
- Cardiovascular and weight-loss outcomes
- Real-world data on treatment adherence and quality of life
🔄 Expanded Indications Beyond Diabetes
- Obesity and weight management
- GLP-1 RAs in cardiovascular risk reduction
- Emerging studies on neurodegenerative disease and NASH
✅ Conclusion & Key Takeaways
- GLP-1 RAs are now considered multi-benefit agents for T2DM and obesity.
- Semaglutide and tirzepatide have shown robust clinical outcomes across multiple domains.
- Future research is needed to evaluate long-term safety and their role in neuroprotection.
- A shift toward broader use in metabolic syndrome is underway, supported by strong evidence.